Osage University Partners has thrown its weight behind a series A2 round for Artizan, which is advancing work undertaken at Yale University.

Artizan Biosciences, a US-based developer of treatments for inflammatory diseases that was spun out of Yale University, has collected $11m in a series A2 round backed by spinout-focused investment firm Osage University Partners (OUP). Biopharmaceutical firm Biohaven Therapeutics and Hatteras Venture Partners co-led the round, which also attracted Connecticut Innovations and Elm Street Ventures. Artizan…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.